Literature DB >> 9458895

Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors.

S C Hobler1, G Tiao, J E Fischer, J Monaco, P O Hasselgren.   

Abstract

Recent studies suggest that sepsis stimulates ubiquitin-dependent protein breakdown in skeletal muscle. The 20S proteasome is the catalytic core of the ubiquitin-dependent proteolytic pathway. We tested the effects in vitro of the proteasome inhibitors N-acetyl-L-leucinyl-L-leucinal-L-norleucinal (LLnL) and lactacystin on protein breakdown in incubated muscles from septic rats. LLnL resulted in a dose- and time-dependent inhibition of protein breakdown in muscles from septic rats. Lactacystin blocked both total and myofibrillar muscle protein breakdown. In addition to inhibiting protein breakdown, LLnL reduced muscle protein synthesis and increased ubiquitin mRNA levels, probably reflecting inhibited proteasome-associated ribonuclease activity. Inhibited muscle protein breakdown caused by LLnL or lactacystin supports the concept that the ubiquitin-proteasome pathway plays a central role in sepsis-induced muscle proteolysis. The results suggest that muscle catabolism during sepsis may be inhibited by targeting specific molecular mechanisms of muscle proteolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458895     DOI: 10.1152/ajpregu.1998.274.1.R30

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  26 in total

1.  Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles.

Authors:  Lydie Combaret; Daniel Taillandier; Dominique Dardevet; Daniel Béchet; Cécile Rallière; Agnès Claustre; Jean Grizard; Didier Attaix
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

2.  Tissue distribution of the "N-end rule" ubiquitin-conjugating enzyme, HR6, in the rat.

Authors:  Andre Tomasino; Lars Klimaschewski
Journal:  Histochem Cell Biol       Date:  2005-05-03       Impact factor: 4.304

Review 3.  Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Authors:  Christine S Muli; Wenzhi Tian; Darci J Trader
Journal:  Chembiochem       Date:  2019-05-24       Impact factor: 3.164

4.  Role of IGF-I and the TNFα/NF-κB pathway in the induction of muscle atrogenes by acute inflammation.

Authors:  O Schakman; M Dehoux; S Bouchuari; S Delaere; P Lause; N Decroly; S E Shoelson; J-P Thissen
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-26       Impact factor: 4.310

5.  Regulation of the Nfkbiz Gene and Its Protein Product IkBζ in Animal Models of Sepsis and Endotoxic Shock.

Authors:  Arturo Casas; Dennis Hawisher; Christian B De Guzman; Stephen W Bickler; Antonio De Maio; David M Cauvi
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

Review 6.  Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia.

Authors:  D Attaix; L Combaret; T Tilignac; D Taillandier
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 7.  Role of the ubiquitin-proteasome pathway in sepsis-induced muscle catabolism.

Authors:  P O Hasselgren
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

8.  Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.

Authors:  L Combaret; C Rallière; D Taillandier; K Tanaka; D Attaix
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

9.  The effect of new proteasome inhibitors, belactosin A and C, on protein metabolism in isolated rat skeletal muscle.

Authors:  T Muthny; M Kovarik; L Sispera; A de Meijere; O V Larionov; I Tilser; M Holecek
Journal:  J Physiol Biochem       Date:  2009-06       Impact factor: 4.158

10.  Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis.

Authors:  Xunbao Duan; François Berthiaume; David Yarmush; Martin L Yarmush
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.